Starton Therapeutics Announces Enrollment Completion for STAR-LLD Phase 1b Clinical Trial in Multiple Myeloma tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
Study enrollment is ahead of schedule with half of the patients enrolled and complete enrollment is expected by Q3/24Early data may suggest superiority in.
Gabrail Cancer & Research Center activated and open to screen patients, with Nash Gabrail, MD as lead investigatorSite activation comes several months ahead of schedule, significantly accelerating Starton’s clinical program timelinePARAMUS, N.J. (BUSINESS WIRE) Starton Therapeutics Inc. (“Starton” or “the Company”.
FDA agrees to the planned Phase 1b study in second-line transplant-ineligible patients in multiple myelomaTreatment regimen will include Velcade® (bortezomib) and dexamethasone and replace oral Revlimid® with STAR-LLDPARAMUS, N.J. (BUSINESS WIRE) Starton Therapeutics Inc. (“Starton” or “the Company”), a clinical s.
FDA agrees to the planned Phase 1b study in second-line transplant-ineligible patients in multiple myeloma
Treatment regimen will include Velcade® and dexamethasone and replace oral. | June 12, 2023